XTAI4106
Market cap75mUSD
Dec 24, Last price
24.45TWD
1D
0.20%
1Q
-5.42%
Jan 2017
-27.77%
Name
Wellell Inc
Chart & Performance
Profile
Apex Medical Corp. provides medical solutions for healthcare professionals worldwide. The company offers wound management products, including Serene Air and Serene Elite, which are alternating pressure redistribution systems for patients with high to very high risk for pressure ulcers; ACS Turn, a lateral turning mattress for prevention of ventilator-associated pneumonia; Pro-care Optima, an alternating pressure redistribution system for patients with high to very high risk of pressure injuries; Pro-care turn, a bilateral turning air mattress for patients with medium to high risk of pressure injuries; Domus Auto, Domus 4, and Verso for patients with medium to high risk of pressure injury; Domus 3 for patients with medium risk of pressure injury; Domus 2s for patients with low to medium risk of pressure injury; Domus 1 for patients in low risk of pressure injury; Sedens 500 and Sedens 400, which are seat cushions; and Flexi-Air, a non-powered hybrid mattress. It also provides respiratory therapy products, such as nasal masks, full face masks, nasal pillows mask, portable suction unit, and compressor nebulizers; iCH Auto and XT Auto for automatic positive airway pressure; XT Prime, XT Sense, and XT Fit for continuous positive airway pressure; and medical equipment. Apex Medical Corp. was founded in 1990 and is headquartered in New Taipei City, Taiwan.
Valuation
Title TWD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|---|
2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | 2014‑12 | |
Income | ||||||||||
Revenues | 2,647,122 -0.62% | 2,663,723 12.20% | 2,374,055 18.46% | |||||||
Cost of revenue | 2,453,062 | 2,477,600 | 2,270,048 | |||||||
Unusual Expense (Income) | ||||||||||
NOPBT | 194,060 | 186,123 | 104,007 | |||||||
NOPBT Margin | 7.33% | 6.99% | 4.38% | |||||||
Operating Taxes | 56,841 | 38,423 | 34,570 | |||||||
Tax Rate | 29.29% | 20.64% | 33.24% | |||||||
NOPAT | 137,219 | 147,700 | 69,437 | |||||||
Net income | 152,172 -5.72% | 161,404 57.86% | 102,247 -2.24% | |||||||
Dividends | (85,775) | (55,501) | (55,501) | |||||||
Dividend yield | 2.92% | 1.86% | 1.86% | |||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
Debt | ||||||||||
Debt current | 223,386 | 322,338 | 381,440 | |||||||
Long-term debt | 184,968 | 222,217 | 219,802 | |||||||
Deferred revenue | 5,361 | |||||||||
Other long-term liabilities | 36,026 | 35,002 | 32,249 | |||||||
Net debt | (279,022) | 80,110 | 77,149 | |||||||
Cash flow | ||||||||||
Cash from operating activities | 455,658 | 82,145 | 19,005 | |||||||
CAPEX | (28,826) | (47,992) | (52,292) | |||||||
Cash from investing activities | (52,895) | (32,901) | (15,923) | |||||||
Cash from financing activities | (200,381) | (145,833) | 81,876 | |||||||
FCF | 322,489 | (32,057) | (84,375) | |||||||
Balance | ||||||||||
Cash | 759,306 | 550,442 | 598,814 | |||||||
Long term investments | (71,930) | (85,997) | (74,721) | |||||||
Excess cash | 555,020 | 331,259 | 405,390 | |||||||
Stockholders' equity | 1,431,391 | 1,892,263 | 1,729,178 | |||||||
Invested Capital | 2,186,427 | 2,383,581 | 2,224,332 | |||||||
ROIC | 6.01% | 6.41% | 3.19% | |||||||
ROCE | 7.06% | 6.86% | 3.96% | |||||||
EV | ||||||||||
Common stock shares outstanding | 101,573 | 101,536 | 101,320 | |||||||
Price | 28.90 -1.70% | 29.40 0.00% | 29.40 2.26% | |||||||
Market cap | 2,935,460 -1.66% | 2,985,158 0.21% | 2,978,808 2.25% | |||||||
EV | 2,661,327 | 3,071,562 | 3,061,145 | |||||||
EBITDA | 287,823 | 279,434 | 197,553 | |||||||
EV/EBITDA | 9.25 | 10.99 | 15.50 | |||||||
Interest | 14,184 | 10,183 | 7,670 | |||||||
Interest/NOPBT | 7.31% | 5.47% | 7.37% |